EMEA-002880-PIP01-20
Key facts
| Invented name |
Jcovden (previously COVID-19 Vaccine Janssen)
|
| Active substance |
COVID-19 vaccine (Ad26.COV2-S (recombinant))
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0059/2021
|
| PIP number |
EMEA-002880-PIP01-20
|
| Pharmaceutical form(s) |
Suspension for injection in cartridge
|
| Condition(s) / indication(s) |
Prevention of Coronavirus disease 2019 (COVID-19)
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Janssen-Cilag International N.V.
Tel. +32 14602111 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|